Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

ImmunoGen exercises put option

Sep. 30, 1999

StressGen completes phase I trial of HspE7

Sep. 28, 1999

TriAb prolongs disease progression in breast cancer patients

Sep. 27, 1999

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

Sep. 24, 1999

FDA accepts IND for ImmunoGen's tumor-activated prodrug

Sep. 23, 1999

Kyowa Hakko begins clinical testing of MAb as melanoma Rx

Sep. 21, 1999

Genzyme Molecular Oncology reports preclinical results, collaboration for aaATIII

Sep. 21, 1999

Biomira updates development activites at recent healthcare conference

Sep. 17, 1999

Boehringer Ingelheim's TNF-alpha-1a launched in Europe for soft tissue sarcoma

Sep. 16, 1999

M-Vax nearing commercialization in several markets

Sep. 16, 1999

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...